ProCE Banner Activity

CheckMate 901 Phase III Trial: First-line Nivolumab + Gemcitabine/Cisplatin vs Gemcitabine/Cisplatin Alone for Unresectable/Metastatic Urothelial Carcinoma

Conference Coverage

Final results of the phase III CheckMate 901 trial demonstrate that first-line nivolumab + gemcitabine/cisplatin significantly improves overall survival vs gemcitabine/cisplatin alone for unresectable/metastatic urothelial carcinoma.

Released: October 30, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc